A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Trial Profile

A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Adenocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 07 Jun 2016 Primary endpoint has not been met. (Best overall response rate), as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Primary endpoint has not been met. (Patients alive without disease progression), as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top